Tempest reports Q3 net loss $3.5M, cash $7.5M; continues strategic alternatives process

Tempest Therapeutics, Inc.

2025-Q3 EPS reported -$5.71

Cash and equivalents $7.5M at Sept 30, 2025, down from $30.3M at Dec 31, 2024.
Net loss Q3 2025: $3.5M ($0.79/share) vs $10.6M ($5.32/share) in Q3 2024.
R&D expenses fell to $0.6M from $7.6M due to reprioritizing toward strategic alternatives.
Company continues strategic alternatives process to maximize stockholder value.
Expects start of TPST-1495 Phase 2 in collaboration with NCI and Cancer Prevention Clinical Trials Network.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-265937
form_type: 8-K
ticker: TPST
cik: 0001544227
company_name: Tempest Therapeutics, Inc.
filed_at: 2025-11-05T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.699022+00:00
generated_at: 2026-05-17T00:16:43.731784+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-265937
json_url: https://secwatch.observer/filing/0001193125-25-265937.json
markdown_url: https://secwatch.observer/filing/0001193125-25-265937.md
text_url: https://secwatch.observer/filing/0001193125-25-265937.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312525265937/0001193125-25-265937-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312525265937/tpst-20251105.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-265937

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.